Team:Penn/Targeting
From 2012.igem.org
(48 intermediate revisions not shown) | |||
Line 9: | Line 9: | ||
.pic1{ float:left; margin:0 40px 0 0; width:150px;} | .pic1{ float:left; margin:0 40px 0 0; width:150px;} | ||
.name{ font-size:20px;} | .name{ font-size:20px;} | ||
- | .figs2{width: | + | .figs2{width:880px; margin:0 auto; overflow:hidden;} |
- | .fignew{font-size:13px; width: | + | .fignew{font-size:13px; width:400px; margin:10px auto; float:left; padding:0 20px 0 20px;} |
.fig{font-size:13px; width:500px; margin:10px auto;} | .fig{font-size:13px; width:500px; margin:10px auto;} | ||
+ | .fig11{font-size:13px; width:570px; margin:10px auto; padding-left:23px;} | ||
</style> | </style> | ||
<br> | <br> | ||
<div class="bigbox"> | <div class="bigbox"> | ||
- | <b><div class="name" align="center">Testing the Displayed HER2 | + | <b><div class="name" align="center">Testing the Displayed HER2 DARPin on Cancer Cells</div></b><br /> |
<p style="color:black;text-indent:30px;"> | <p style="color:black;text-indent:30px;"> | ||
Line 23: | Line 24: | ||
<p style="color:black;text-indent:30px;"> | <p style="color:black;text-indent:30px;"> | ||
- | To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure | + | To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure 1).</p> |
- | |||
- | |||
- | |||
- | |||
<div class="figs2"> | <div class="figs2"> | ||
- | <div class="fignew"><div align="center"><img src="https://static.igem.org/mediawiki/2012/ | + | <div class="fignew"><div align="center"><img src="https://static.igem.org/mediawiki/2012/e/e0/SKBR3_%28%2BDAPI%29_%28%2BAB1%29_%28%2BAB2%29_630x.jpg" height="400" width="400"><br> |
- | <b>Figure | + | <b>Figure 1</b></div>Figure 1: SKBR3 cells over-express HER2 on their surface. Red indicates HER2 (Alexa-Fluor 647), Blue indicates DAPI.</div> |
- | <div class="fignew"><div align="center"><img src="https://static.igem.org/mediawiki/2012/ | + | <div class="fignew"><div align="center"><img src="https://static.igem.org/mediawiki/2012/7/7a/HER2-Breast-Tissue.jpg" height="400" width="400"><br> |
- | <b>Figure | + | <b>Figure 2</b></div>Figure 2: Images of breast cancer cells removed from human tissue reveal similar HER 2 expression to results obtained in Figure 2. </div></div> |
- | + | ||
+ | |||
+ | <p style="color:black;text-indent:30px;">To assay whether our DARPin-displaying E. coli bound to SKBR3 cells preferentially, we conducted experiments in which our bacteria were co-incubated with SKBR3 or HEK293T cells. The DARPin-displaying bacteria were co-transformed with constitutively expressed eGFP (pACBB-eGFP plasmid) for easy visualization. The goal was to show SKBR3-specific binding of eGFP labeled bacteria, and only when they were induced with IPTG to produce INPNC-DARPin. Preliminary results are exciting and show preferential binding to SKBR3 cells. In culture plates with low-HER2 HEK293T cells, no green bacteria were observed bound to the cells. IPTG-induced bacteria bound selectively to SKBR3 cells and we visualized this binding by confocal microscopy (Figure 3).</p> | ||
<div align="center"> | <div align="center"> | ||
<img src="https://static.igem.org/mediawiki/2012/a/a6/Darpinbinding2.png" width="794" height="425" /></div> | <img src="https://static.igem.org/mediawiki/2012/a/a6/Darpinbinding2.png" width="794" height="425" /></div> | ||
- | </div> | + | |
+ | <div class="fig11"><b>Figure 3</b>: SKBR3 cells overexpress HER2 and DARPin-displaying bacteria bind to their surface. Red indicates HER2 (Alexa-Fluor 647). Blue indicates DAPI. Green indicates eGFP. Bacteria were co-incubated at a Multiplicity of Infection of 200:1 and washed three times after co-incubation followed by a 50ug/mL gentamicin protection assay.</p></div> | ||
+ | |||
+ | <br> | ||
+ | <br> | ||
+ | Taking a closer look at the SKBR3 + Induced Bacteria group, one can observe our eGFP labeled bacteria bound directly to the HER2 on SKBR3 cells (Figure 4) | ||
+ | <br> | ||
+ | <br> | ||
+ | <div align="center"> | ||
+ | <img src="https://static.igem.org/mediawiki/2012/9/94/SKBR3_closeup_binding.png" width="900" height="494.6" /></div> | ||
+ | |||
+ | <div class="fig11"><b>Figure 4</b>: Direct binding of INPNC-DARPin expressing, eGFP-labeled bacteria to SKBR3 cells.</p></div> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | <br> | ||
+ | <br> | ||
+ | <b>Conclusion</b> | ||
+ | <p style="color:black;text-indent:30px;"> | ||
+ | In summary, we demonstrated surface display of DARPin H10-2-G3 for the first time and have demonstrated that our DARPin-displaying bacteria can target cancer cells <i>in vitro</i>. We also developed a generalized surface display BioBrick for any iGEM team to use.<br /> </div></div> | ||
</html> | </html> |
Latest revision as of 02:59, 27 October 2012
After verifying that the DARPin was displayed on the cell surface, we sought to test whether it could allow binding to HER2-overexpressing cancer cells. We were generously provided SKBR3 cells by the lab of Matthew Lazzara. These cells are derived from breast cancer cells and over-express HER2. We also obtained Human Embryonic Kidney (HEK) 293T cells, which express a low amount of HER2, to act as controls.
To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure 1).
![](https://static.igem.org/mediawiki/2012/e/e0/SKBR3_%28%2BDAPI%29_%28%2BAB1%29_%28%2BAB2%29_630x.jpg)
Figure 1
![](https://static.igem.org/mediawiki/2012/7/7a/HER2-Breast-Tissue.jpg)
Figure 2
To assay whether our DARPin-displaying E. coli bound to SKBR3 cells preferentially, we conducted experiments in which our bacteria were co-incubated with SKBR3 or HEK293T cells. The DARPin-displaying bacteria were co-transformed with constitutively expressed eGFP (pACBB-eGFP plasmid) for easy visualization. The goal was to show SKBR3-specific binding of eGFP labeled bacteria, and only when they were induced with IPTG to produce INPNC-DARPin. Preliminary results are exciting and show preferential binding to SKBR3 cells. In culture plates with low-HER2 HEK293T cells, no green bacteria were observed bound to the cells. IPTG-induced bacteria bound selectively to SKBR3 cells and we visualized this binding by confocal microscopy (Figure 3).
![](https://static.igem.org/mediawiki/2012/a/a6/Darpinbinding2.png)
Taking a closer look at the SKBR3 + Induced Bacteria group, one can observe our eGFP labeled bacteria bound directly to the HER2 on SKBR3 cells (Figure 4)
![](https://static.igem.org/mediawiki/2012/9/94/SKBR3_closeup_binding.png)
Conclusion
In summary, we demonstrated surface display of DARPin H10-2-G3 for the first time and have demonstrated that our DARPin-displaying bacteria can target cancer cells in vitro. We also developed a generalized surface display BioBrick for any iGEM team to use.